Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 17/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9469212 | 0.91 | MME (0.85) | MME | |
| SCHEMBL9469210 | 0.91 | MME (0.85) | MME | |
| Candoxatrilat SCHEMBL123669 | 0.90 | MME (1.00) | MME | |
| Candoxatrilat SCHEMBL389959 | 0.90 | MME (1.00) | MME | |
| Candoxatrilat SCHEMBL9469695 | 0.90 | MME (1.00) | MME | |
| Candoxatrilat SCHEMBL389958 | 0.90 | MME (1.00) | MME | |
| SCHEMBL4436826 | 0.89 | MME (0.67) | MME | |
| SCHEMBL9470616 | 0.86 | MME (0.80) | MME | |
| SCHEMBL9470608 | 0.86 | MME (0.80) | MME | |
| SCHEMBL9469989 | 0.84 | MME (0.78) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | REN, MME, ACE | MME 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.